Literature DB >> 28533059

Graft-versus-Host Disease of the Gut: A Histologic Activity Grading System and Validation.

David Myerson1, Gideon Steinbach2, Ted A Gooley3, Howard M Shulman4.   

Abstract

The pathologic interpretation of gut biopsies in hematopoietic cell transplant recipients to assess graft-versus-host disease (GVHD) is well accepted and supplements clinical and endoscopic findings. However, the histologic activity grading of GVHD is controversial, with attempts to predict prognosis or response to treatment largely unsuccessful. GVHD is being diagnosed earlier in its course, raising the possibility that the pathologic grading system can be profitably modified. We developed a histologic activity grading system designed to replace the commonly used modified Lerner grading systems. Our system stratifies the low-level Lerner grade I category into 4 activity grade categories, based on the average frequency of apoptotic cells. The results are expressed as ordinal categories: GVHD of minimal, mild, moderate, severe histologic activity, or severe histologic activity with destruction (activity grades 1 to 5). In a retrospective study, we studied 87 consecutive cases with 201 post-transplantation specimens (median, 48 days; range, 18 to 1479 days) of stomach, duodenum, and colorectum, which had been activity graded at the time of the original diagnosis. Most of the biopsies diagnosed as GVHD were low grade-minimal (11%) or mild (71%) histologic activity. We hypothesized that the higher activity grades would be associated with more therapeutic intervention. The odds of increased therapy in the combined all-site specimens were increased as activity grade increased (odds ratio, 2.9 [95% confidence interval {CI}, 1.9 to 4.5]; P = < .0001). Thus, our grading system was validated. To investigate whether the activity grade was associated with therapy within the formerly undivided Lerner grade I category, the analysis was restricted to these 174 all-site specimens. The validation result was similar (odds ratio, 3.1 [95% CI, 1.3 to 7.2]; P = .009). This result interestingly suggests that there is useful information hidden in the Lerner grade I category, which could potentially guide immediately actionable treatment decisions. This histologic activity grade system has been in use at our institution for over 2 years with good acceptance.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activity grading; GVHD; Graft-versus-host disease; Pathology; Therapy

Mesh:

Substances:

Year:  2017        PMID: 28533059      PMCID: PMC6289287          DOI: 10.1016/j.bbmt.2017.05.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  57 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

2.  Endoscopic diagnosis of pediatric acute gastrointestinal graft-versus-host disease.

Authors:  Mutaz Sultan; Jonathan Ramprasad; M Kyle Jensen; David Margolis; Steven Werlin
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-10       Impact factor: 2.839

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

4.  Gastric graft-versus-host disease: a blinded histologic study.

Authors:  K Washington; R C Bentley; A Green; J Olson; W R Treem; H R Krigman
Journal:  Am J Surg Pathol       Date:  1997-09       Impact factor: 6.394

Review 5.  The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.

Authors:  Alaa M Ali; John F DiPersio; Mark A Schroeder
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-05       Impact factor: 5.742

6.  Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease.

Authors:  Adam J Gomez; Sally Arai; John P Higgins; Neeraja Kambham
Journal:  Arch Pathol Lab Med       Date:  2016-06       Impact factor: 5.534

7.  Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility.

Authors:  Andreas Kreft; Anja Mottok; Ildiko Mesteri; Diana M Cardona; Anne Janin; Anja A Kühl; Mindaugas Andrulis; Andrea Brunner; Howard M Shulman; Giovanni Negri; Alexandar Tzankov; Elisabeth Huber
Journal:  Virchows Arch       Date:  2015-07-12       Impact factor: 4.064

8.  Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.

Authors:  Joshua Melson; Shriram Jakate; Henry Fung; Sally Arai; Ali Keshavarzian
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

9.  Clinical severity scores in gastrointestinal graft-versus-host disease.

Authors:  Julie Abraham; Anne Janin; Jean-Marc Gornet; Régis Peffault de Latour; Marie Robin; Aliénor Xhaard; Flore Sicre de Fontebrune; Jean Yves Mary; Matthieu Allez; Raphael Porcher; Gérard Socié
Journal:  Transplantation       Date:  2014-05-15       Impact factor: 4.939

Review 10.  Pathology of graft-versus-host disease in the gastrointestinal tract.

Authors:  Kay Washington; Madan Jagasia
Journal:  Hum Pathol       Date:  2009-07       Impact factor: 3.466

View more
  3 in total

1.  Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.

Authors:  Khalid Amin; Usman Yaqoob; Brittney Schultz; Byron P Vaughn; Alexander Khoruts; Justin R Howard; Todd E DeFor; Colleen Forster; Carolyn Meyer; Isha Gandhi; Daniel J Weisdorf; Armin Rashidi; Margaret L MacMillan; Bruce R Blazar; Angela Panoskaltsis-Mortari; Shernan G Holtan
Journal:  Mod Pathol       Date:  2018-11-13       Impact factor: 7.842

2.  Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry.

Authors:  Jan-Malte Placke; Josefine Rawitzer; Henning Reis; Jassin Rashidi-Alavijeh; Elisabeth Livingstone; Selma Ugurel; Eva Hadaschik; Klaus Griewank; Kurt Werner Schmid; Dirk Schadendorf; Alexander Roesch; Lisa Zimmer
Journal:  Front Oncol       Date:  2021-08-11       Impact factor: 6.244

3.  Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Authors:  Diana M Cardona; Claire J Detweiler; Michael J Shealy; Anthony D Sung; Daniel M Wild; Martin H Poleski; Bryan L Balmadrid; Constance T Cirrincione; David N Howell; Keith M Sullivan
Journal:  Arch Pathol Lab Med       Date:  2018-04-26       Impact factor: 5.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.